Study Summary
This trial is testing a new drug for people with relapsed or refractory AML with monocytic differentiation and CMML. They are trying to find the best dose of the new drug.
- Chronic Myelomonocytic Leukemia
- Acute Myeloid Leukemia with Monocytic Differentiation
- Acute Myeloid Leukemia M4
- Acute Myeloid Leukemia (AML) M5
- Acute Myelogenous Leukemia (AML) in Relapse
- Acute Myeloid Leukemia
Treatment Effectiveness
Effectiveness Progress
Study Objectives
8 Primary · 10 Secondary · Reporting Duration: Through study completion, an average of 1 year
Trial Safety
Safety Progress
Trial Design
9 Treatment Groups
Dose Expansion of IO-202 plus Azacitidine CMML
1 of 9
Dose Expansion of IO-202 plus Azacitidine AML
1 of 9
Dose Expansion of IO-202 plus Azacitidine + Venetoclax (Ven)
1 of 9
Dose Expansion of IO-202
1 of 9
Dose Escalation
1 of 9
Dose Expansion
1 of 9
Dose Escalation of IO-202 Plus Azacitidine
1 of 9
Dose Escalation of IO-202
1 of 9
Dose Expansion of IO-202 plus Azacitidine
1 of 9
Experimental Treatment
122 Total Participants · 9 Treatment Groups
Primary Treatment: IO-202 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Could you elaborate on the potential hazards of IO-202?
"Limited safety and efficacy data for IO-202 warrants a score of 1 on our team's assessment scale. As this is a Phase 1 trial, the risks associated with participating are relatively high." - Anonymous Online Contributor
What primary goals has this experiment been designed to accomplish?
"The primary goal of this medical experiment, which will be observed from the first dose to 30 days following the last treatment instance, is assessing safety as indicated by adverse events. Secondary objectives include quantifying IO-202's PK through AUC measurement, gauging response rates in patients with anti-drug antibodies, and determining Cmax for IO-202." - Anonymous Online Contributor
In what geographical locations is this experiment taking place?
"The list of medical centres offering this clinical trial are numerous. Winship Cancer Institute at Emory University in Atlanta, the University of California San Francisco and Davis, as well as other twelve sites across the nation all provide access to this treatment." - Anonymous Online Contributor
Are there still opportunities for individuals to participate in this experiment?
"The trial, initially posted on September 14th 2020 and last revised on May 3rd 2022, is still seeking participants. This fact can be confirmed by visiting clinicaltrials.gov." - Anonymous Online Contributor
What is the maximum number of individuals eligible for this experiment?
"Affirmative. According to clinicaltrials.gov, the research in question is currently seeking volunteers and opened recruitment on September 14th 2020. As of May 3rd 2022, 119 participants need to be recruited at a dozen different sites for this study." - Anonymous Online Contributor